General Information of Drug Combination (ID: DCRDDPW)

Drug Combination Name
Ginsenoside Rb1 Idarubicin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Ginsenoside Rb1   DMF70AB Idarubicin   DMM0XGL
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 16.46
Bliss Independence Score: 16.46
Loewe Additivity Score: 24.13
LHighest Single Agent (HSA) Score: 24.15

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Ginsenoside Rb1 Interacts with 23 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-glucosidase (bglA) DEUO7V8 A0A509DD13_9STRE Metabolism [4]
Beta-glucosidase (bglA) DE4LKZ9 A0A3D1ZWL4_9BIFI Metabolism [4]
Beta-glucosidase (bglA) DEM6GYO A0A351PC96_9FIRM Metabolism [5], [4]
Beta-glucosidase (bglA) DE9N4OU C6WCL5_ACTMD Metabolism [6]
Beta-glucosidase (bglA) DERPJZ6 A0A4Q4LS82_BIFAN Metabolism [7]
Beta-glucosidase (bglA) DEVLXCG R7LVY8_9FUSO Metabolism [4]
Beta-glucosidase (bglA) DEUQTKA A0A249DCH3_LACRH Metabolism [7]
Beta-glucosidase (bglA) DEXRUS1 A0A267WL33_9BIFI Metabolism [8]
Beta-glucosidase (bglA) DERX7ML A0A3B8TKP6_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEOHI3U A0A0P0FEZ9_BACT4 Metabolism [8]
Beta-glucosidase (bglA) DE46IH1 A0A1T4QCU7_9PROT Metabolism [9]
Beta-glucosidase (bglA) DEE8WXK A0A076JJU4_BIFAD Metabolism [8]
Beta-glucosidase (bglA) DECBSVP A0A126SWK8_9BIFI Metabolism [8]
Beta-glucosidase (bglA) DEAVLU4 BGLFU_BIFBR Metabolism [8]
Beta-glucosidase (bglA) DEPBQES BGLS_BUTFI Metabolism [8]
Beta-glucosidase (bglA) DEGVUWH A0A174JG46_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEE8RS0 A0A174GPV4_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEC0M8H A0A174ZK85_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DE2OMS0 A0A173UNF6_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEPUNVR A0A395V8H8_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEX7SAW A0A3R6A2W5_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEE3I1P A0A412BAD0_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEASJG5 A5ZMW4_9FIRM Metabolism [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DME(s)
Ginsenoside Rb1 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily E member 1 (KCNE1) OTZNQUW9 KCNE1_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------
Indication(s) of Idarubicin
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [2]
Acute myeloid leukaemia 2A60 Approved [3]
Adult acute monocytic leukemia N.A. Approved [2]
Childhood acute megakaryoblastic leukemia N.A. Approved [2]
Leukemia N.A. Approved [2]
Idarubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [12]
------------------------------------------------------------------------------------
Idarubicin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [13]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [14]
------------------------------------------------------------------------------------
Idarubicin Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [15]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [15]
------------------------------------------------------------------------------------
Idarubicin Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [16]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Activity [11]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Idarubicin FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
4 Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
5 Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol. 1998 Oct;50(10):1155-60.
6 Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
7 Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
8 Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
9 Genus Enhydrobacter Staley et al. 1987 should be recognized as a member of the family Rhodospirillaceae within the class Alphaproteobacteria. Microbiol Immunol. 2012 Jan;56(1):21-6.
10 Ginsenosides may enhance the functionality of human embryonic stem cell-derived cardiomyocytes in vitro. Reprod Sci. 2014 Oct;21(10):1312-8. doi: 10.1177/1933719114525269. Epub 2014 Mar 10.
11 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
14 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
15 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
16 The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.